List view / Grid view
27 July 2015 | By Coulter Partners
Global Life Sciences search specialist, Coulter Partners is pleased to announce the appointments of Emma Hiom as Principal and Zubair Yusuf as Senior Associate in the UK...
27 July 2015 | By Victoria White
Daklinza has been approved by the US FDA, marking the first time patients with chronic HCV genotype 3 have a 12-week, once-daily, all-oral treatment option...
27 July 2015 | By Victoria White
The CHMP has adopted a positive opinion for the combination of Tafinlar and Mekinist for the treatment of adult patients with advanced melanoma...
24 July 2015 | By Victoria White
The CHMP has adopted a positive opinion for on marketing authorisation of Fexeric, recommending its approval for the treatment of hyperphosphatemia in CKD...
24 July 2015 | By Victoria White
An independent expert review of alteplase has provided a firm reassurance that it is safe and effective for use up to 4.5 hours after the onset of symptoms...
24 July 2015 | By Victoria White
Regorafenib has been recommended for use on NHS Wales as a third-line treatment for patients with advanced gastrointestinal stromal tumours (GIST).
24 July 2015 | By Victoria White
The CHMP has adopted a positive scientific opinion for Mosquirix, making it the first vaccine for the prevention of malaria to reach such a milestone...
24 July 2015 | By Victoria White
The CHMP has adopted a positive opinion recommending the approval of Shire’s Intuniv for the treatment of ADHD in children and adolescents...
24 July 2015 | By Victoria White
A study of more than 30,000 women shows that aromatase inhibitors substantially reduce the risk of death in postmenopausal women ER-positive breast cancer...
23 July 2015 | By Victoria White
The global market for type 2 diabetes mellitus therapeutics will rise in value from $23.5 billion in 2014 to an estimated $39 billion by 2021, driven primarily by rising disease prevalence and the continued uptake of recently approved and emerging branded treatments, according to business intelligence provider GBI Research.
23 July 2015 | By Victoria White
Amgen has submitted a sNDA to the US FDA for Kyprolis to seek an expanded indication for the treatment of patients with relapsed multiple myeloma...
23 July 2015 | By Victoria White
The EMA has validated two type II variation applications which seek to extend the indication of Opdivo in non-squamous NSCLC and advanced melanoma...
23 July 2015 | By Victoria White
The EC has approved Merck’s Keytruda (pembrolizumab) for the treatment of advanced (unresectable or metastatic) melanoma in adults...
23 July 2015 | By Victoria White
New data shows that knowledge of amyloid status as determined by Florbetapir F 18 Injection imaging altered diagnosis and management of patients...
23 July 2015 | By Victoria White
Depomed has confirmed that it has received an unsolicited proposal from Horizon Pharma to acquire all of the outstanding shares of Depomed...
